CSPC Pharmaceutical (HKG:1093) initiated two clinical trials at their first centers in China, according to two Hong Kong bourse filings on Thursday.
The pharma company began a phase II study of Sirolimus for Injection to treat patients with progressive/symptomatic epithelioid haemangioendothelioma.
A phase III clinical trial of SYS6043 versus chemotherapy for the treatment of participants with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer was also initiated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments